East Tallinn Central Hospital — Clinical Trial Site

31 Registered trials

6 Currently recruiting

Organisation

East Tallinn Central Hospital

Location

Tallinn, Estonia

Identifier

ORG-100028449

Address

Ravi Tn 18, Kesklinna Linnaosa, 10138, Estonia

Departments

#3700: Rheumatology Department
#7205: Cardiology
1955: Clinic of Internal Medicine, Centre of Cardiology
2022: Clinic of Internal Medicine, Department of Rheumatology
2201: Internal clinic, heart clinic (Südamekeskus)
93123002
Center of Gastroenterology
Centre of Oncology
Clinic of Internal Medicine, Centre of Rheumatology
Departmenf of Oncology
EE10002: Cardiology
Endocrinology
Endocrinology Center
Eye Clinic
Gastroenterology Centre (Ravi 18, 10138 Tallinn, Estonia)
Gastroenterology Department
N/A
not applicable
Ophthalmology
Rheumatology
Rheumatology department

Clinical trials at this site (31)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8… Recruiting

2025-524575-22-00 Neovascular age-related macular degeneration (NVAMD) 10 2026-06-30
A Phase 2 Randomized Trial Evaluating Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mass (ARTEMIS) Recruiting

2024-515610-41-00 Postmenopausal Osteoporosis 4 2025-09-11
A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with… Recruiting

2024-516616-24-00 Acromegaly 5 2025-07-23
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended

2023-503265-27-00 Participants with Untreated T4N0 or Stage III dMMR/MSI- 5 2023-11-23
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended

2022-500953-17-00 Moderately to severely active ulcerative colitis 4 2023-03-23
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Lupus nephritis 5 2022-07-14
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo… Ended

2023-505477-33-00 Psoriatic Arthritis 5 2019-06-18
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Ulcerative Colitis 5 2017-01-02
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 Post-Menopausal Osteoporosis 5 2024-01-09